Parsi Meghana, Desai Milap H, Desai Devashish, Singhal Sachi, Khandwala Pushti M, Potdar Rashmika R
Dept of Internal Medicine, Crozer-Chester Medical Center, 1 Medical Center Blvd, Upland, PA, USA.
Drexel University College of Medicine, Philadelphia, PA, USA.
Med Oncol. 2021 Jun 28;38(8):89. doi: 10.1007/s12032-021-01537-3.
Although management of advanced prostate cancer is evolving, a lot of work remains to be done for patients who have exhausted all options. Molecular targeting of prostate specific membrane antigen (PSMA) is valuable not only for diagnostic but also for therapeutic reasons. PSMA is thus considered to be useful in a theranostic approach. PSMA scans are upcoming diagnostic modalities which detect metastatic lesions that are missed by conventional imaging modalities. PSMA ligand therapy is also an upcoming treatment modality that has been proven to be beneficial with minimal toxicity in patients with advanced prostate cancer that have progressed on prior therapy. In this review article, we summarize the current knowledge regarding PSMA diagnostics and PSMA ligand therapies and discuss their implication in the treatment of advanced prostate cancer.
尽管晚期前列腺癌的管理正在不断发展，但对于那些已用尽所有治疗选择的患者而言，仍有许多工作有待完成。前列腺特异性膜抗原（PSMA）的分子靶向不仅对诊断有价值，对治疗也很有价值。因此，PSMA被认为在诊疗一体化方法中很有用。PSMA扫描是即将出现的诊断方式，可检测出传统成像方式遗漏的转移病灶。PSMA配体疗法也是一种即将出现的治疗方式，已被证明对先前治疗后病情进展的晚期前列腺癌患者有益，且毒性极小。在这篇综述文章中，我们总结了关于PSMA诊断和PSMA配体疗法的当前知识，并讨论它们在晚期前列腺癌治疗中的意义。
